Related readings:  Hangzhou drug firm stops operation  Harbin Pharmaceutical Drug maker to list shares overseas  Biotech drug to play major role

Harbin Pharmaceutical's sales declined, and market share was reduced after the National Development and Reform Commission cut drug prices three times since the start of 2006, the company said in a filing with the Shanghai Stock Exchange yesterday. It didn't specify how much it expects sales or profit to fall.

In the most recent move, the NDRC cut prices on 354 types of drugs and medicine, by 20 percent on average, the company said in the filing. The company also cited rising costs of raw materials and energy and increasing competition as reasons for its profit to decline, Bloomberg News reported.

The company said it plans to raise US$150 million in a share sale this year, the South China Morning Post said on January 19, citing unidentified people. The shares will be traded in Hong Kong.

(For more biz stories, please visit Industry Updates)